Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volixibat in NASH
NCT02787304Phase 2Terminated
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Oct 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of volixibat in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Number of Subjects Achieving Binary Response on Liver Histology Between Volixibat (SHP626) and Placebo at 48 weeks. Started Oct 2016; status: terminated.
02
Drugs
volixibat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02787304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02787304.